- Home
- OKYO vs IMA Comparison
OKYO vs IMA Comparison
Compare OKYO & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OKYO | IMA |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United Kingdom | United States |
| Employees | N/A | 17 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.3M | 66.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | OKYO | IMA |
|---|---|---|
| Price | $1.47 | $5.79 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | $6.33 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 160.4K | 8.4K |
| Earning Date | 07-18-2025 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.34 | $3.94 |
| 52 Week High | $3.35 | $17.50 |
Technical Indicators
Market Signals| Indicator | OKYO | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 46.71 | 43.53 |
| Support Level | $1.45 | $5.36 |
| Resistance Level | $1.72 | $6.13 |
| Average True Range (ATR) | 0.12 | 0.31 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 29.40 | 22.45 |
Price Performance
Historical ComparisonAbout OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.